Mode
Text Size
Log in / Sign up
N/A Completed N=61,737

Treximet ™ Pharmacy Budget Impact Model Database Validation Study

Migraine Disorders
Source: ClinicalTrials.gov NCT01332500 ↗
Enrolled (actual)
61,737
Serious AEs
—
Results posted
Apr 2011
Primary outcomePrimary: Mean Number of Triptan Tablets Per Participant in 6-month Follow-up Period: Treatment-naïve Analysis — 17.7; 18.4; 19.2; 21.5 tablets per participant — p=<0.001

Summary

The purpose of this retrospective claims database study was to compare the change in migraine-related prescription (i.e. NSAIDs, Opioids, Ergots) utilization among migraine suffers following initiation of Treximet ™ (sumatriptan/naproxen) compared with subjects initiating treatment with other orally available triptans. The study was used to validate the migraine-related prescription utilization patterns predicted by the Treximet ™ Budget Impact Model. The SourceLx dataset from the family of Wolters Kluwer databases was used for this analysis. The database contains 30% of prescription claims filled in the United States (US), approximately 160 million patient lives. The data has broad representative coverage at both the geographic and payment levels.

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Number of Triptan Tablets Per Participant in 6-month Follow-up Period: Treatment-naïve Analysis
17.7; 18.4; 19.2; 21.5; 75.8; 80.1 <0.001 sig
PRIMARY
Mean Health Plan Cost Per Participant for Migraine-related Medications in 6-month Follow-up Period: Treatment-naïve Analysis
284; 333; 9; 9; 38; 43 <0.001 sig
PRIMARY
Mean Total Cost (Health Plan Plus Participant Copay Costs) Per Participant for Migraine-related Medications in 6-month Follow-up Period: Treatment-naïve Analysis
349; 397; 11; 12; 49; 54 <0.001 sig
PRIMARY
Mean Number of Triptan Tablets Per Participant in 6-month Follow-up Period: Treatment-switch Analysis
24.4; 24.4; 20.9; 22.9; 88.4; 87.4 0.866
PRIMARY
Mean Health Plan Cost Per Participant for Migraine-related Medications in 6-month Follow-up Period: Treatment-switch Analysis
375; 425; 8; 10; 47; 51 <0.001 sig
PRIMARY
Mean Total Cost (Health Plan Plus Participant Copay Costs) Per Participant for Migraine-related Medications in 6-month Follow-up Period: Treatment-switch Analysis
462; 496; 12; 13; 61; 62 <0.001 sig

Eligibility Criteria

Inclusion Criteria

  • At least one prescription claim for either Treximet ™ or orally administered triptan
  • at least 18 years of age at index Rx date
  • at least one prescription claim for any medication in the pre- and post-index period (proxy for continuous enrollment)

Exclusion Criteria

  • Subjects receiving nasal sumatriptan at any time
  • Subjects over 65 years of age
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01332500). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search